Clinical Trial

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated June 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-01; most recent amendment 2024-08-16.
Trial Details
NCT Number NCT06202755
Lead Sponsor Kafrelsheikh University
Conditions Ischemic Stroke
Enrollment 580 participants
Start Date 2024-03-30
Primary Completion 2025-06-12 (estimated)
Study Completion 2025-07-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-20